WhiteLab Genomics utilizes a proprietary platform that combines graph knowledge technology and machine learning to optimize the design of payloads and vectors for gene and cell therapies. This technology accelerates the development process, reducing costs and time to market for genomic medicines, making them more accessible to patients.
Funding
$10.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
DGOCFounders
Product
Problem
Genomic medicine development is often slow and costly due to the complexities of payload and vector design, which require extensive datasets and in-silico simulations. Optimizing these designs and assessing genotoxicity can be challenging, hindering the efficient development of gene and cell therapies.
Solution
WhiteLab Genomics offers an AI-driven platform that accelerates the discovery and development of genomic medicines. The platform leverages graph knowledge technology and machine learning to optimize payload and vector design for gene, RNA, and cell therapies. By providing in-silico simulations based on exhaustive datasets, the platform enables scientists to answer key scientific and technological questions, such as optimizing payload and vector design, assessing genotoxicity, and identifying optimal experimental protocols for in vivo and in vitro strategies. This approach reduces the development time and costs associated with bringing genomic medicines to market.
Target Audience
The primary audience includes scientists and researchers in the field of genomic medicine, particularly those focused on gene therapy, RNA therapy, and cell therapy.
Features
- AI-powered platform for optimizing payload and vector design
- Graph knowledge technology and machine learning algorithms
- In-silico simulations based on exhaustive datasets
- Genotoxicity assessment capabilities
- Identification of optimal experimental protocols for in vivo and in vitro strategies
- Support for gene therapy, RNA therapy, and cell therapy development